Funding for this research was provided by:
National Natural Science Foundation of China (NSFC-31870863)
Article History
Received: 18 September 2020
Accepted: 15 November 2020
First Online: 19 January 2021
Competing interests
: A.V. received a contract from Bristol Myers-Squibb to study the mechanism of action of the anti-SLAMF7 monoclonal antibody elotuzumab in multiple myeloma. He was also a consultant for Boehringer-Ingelheim on the topic of the SIRPα-CD47 blockade in anticancer immunotherapy. The authors declare no competing interests.